nach oben

Erschienen in:

01.10.2023 | News item

CDER introduces measures to reduce risk of stimulant use disorder

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The US FDA Center for Drug Evaluation and Research (CDER) is introducing measures to reduce the risk of stimulant use disorder in patients prescribed stimulants such as Adderall (amfetamine/dexamfetamine), Ritalin or Concerta (methylphenidate), or Vyvanse (lisdexamfetamine) for disorders such as attention-deficient hyperactivity disorder (ADHD) or binge-eating disorder. …

CDER Takes Measures to Tackle Stimulant Use Disorder Internet Document : 3 Oct 2023. Available from: URL: https://www.fda.gov/drugs/news-events-human-drugs/cder-takes-measures-tackle-stimulant-use-disorder

Titel: CDER introduces measures to reduce risk of stimulant use disorder
Publikationsdatum: 01.10.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-47728-y

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Multiple drugs

Aspirin

Multiple drugs

Multiple drugs

Sildenafil

Isotretinoin-related psychiatric disorders and sexual dysfunction